Research & Ethics

Prolia compared with Alendronate in Women With Osteoporosis Polia

Comparative Persistence With Prolia and Weekly Alendronate in 6 Asia-Pacific countries: a Prospective Observational Study

You are eligible if you:

• are a Post Menopausal Female with Osteoporosis
• take Prolia (Denosumab) or Alendronate (Fosamax)

More information and Consent Form (PDF, 232KB)

Diabetes treatment for heart disease GPGN

The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)

You are eligible if you:
• are at least 40 years of age
• have been diagnosed with type 2 diabetes
• have an established cardiovascular disease (coronary artery disease, cerebrovascular disease, or peripheral arterial disease).

More information (PDF, 793KB)

Consent Form (PDF, 306KB)

 The Metformin Aneurysm Trial (MAT)

An investigator initiated and conducted, multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial to determine the effect of metformin on abdominal aortic aneurysm (AAA) associated events, including AAA repair and AAA mortality (due to aneurysm rupture).

You may be eligible if you:

• have an abdominal aortic aneurysm
• are aged between 18 – 79 years old
• are not taking metformin

More information (PDF, 977KB)

Consent Form (PDF, 515KB)

Weight Loss Medication

A Phase II, randomized, double blind, parallel group,46 weeks dose-finding study of BI 456906 administered once weekly subcutaneously compared with placebo in patients with obesity or overweight

You are eligible if you:

• are aged between 18 - 75 years, inclusive
• are obese or overweight (BMI equal to or above 27kg/m2)
• have not had a dramatic change in weight over the last 12 weeks
• do not have Type I or Type II diabetes

More information (PDF, 125KB)

Consent Form (PDF, 301KB)

Potential New Treatment for People with Chronic Kidney Disease

Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy
and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with
empagliflozin, in patients with diabetic and non-diabetic chronic kidney disease.
You may be eligible if you:

• are 18 years of age or older
• have diabetic or non-diabetic Chronic kidney disease
• are currently receiving medication for your condition

More Information (PDF,656KB) 

Consent Form (PDF,493KB)

Consent Form (DOC,182KB)

A new Novavax vaccine for the treatment of the Omicron COVID variant.

A Phase 3, Randomized, Observer Blinded Study to Evaluate the Safety and Immunogenicity of Two Booster Doses of the NVX-CoV2515 and Bivalent SARS-CoV-2 rS Vaccines in Adults Previously Vaccinated with Other COVID-19 Vaccines.

You may be eligible if you:

• are aged 18 to 64 years of age
• have previously received 2 or 3 doses of either the Moderna and/or Pfizer/BioNTech vaccines
• are in good general health, as determined by medical history, physical exam, and vital signs
• have no current autoimmune or immunodeficiency disease/condition
• have not had previous allergic reactions to vaccines

More Information (PDF,3.16MB)

Consent Form (PDF,326KB)

Consent Form (DOC,115KB)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity

You are eligible if you:

• are overweight (BMI>27kg/m2)
• do not have diabetes
• have established cardiovascular disease (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) OR can answer yes to two of the following:         
  • are a current smoker 
  • have high cholesterol 
  • have high blood pressure 
  • have kidney disease 
  • have prediabetes

More information (PDF 2.5MB)

Participant Information Sheet and consent form (197KB)

Access our Facebook page